Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism

References

• Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A. (1998). Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:12208–13.
   PubMed Web of Science ®Google Scholar
• Blumberg B, Sabbagh W, Jr Juguilon, H, Bolado J, Jr van, Meter CM, Ong ES, Evans RM. (1998). SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195–205.
   PubMed Web of Science ®Google Scholar
• Bosch TM, Deenen M, Pruntel R, Smits PH, Schellens JH, Beijnen JH, Meijerman I. (2006). Screening for polymorphisms in the PXR gene in a Dutch population. Eur J Clin Pharmacol 62:395–9.
   Google Scholar
• Brodsky L, Ivanov, VV, Kalaidzidis YL, Leontovich, AM, Nikolaev, VK, Feranchuk, SI, Drachev, VA. (1995). GeneBee-NET:Internet-based server for analysing biopolymers structure. Biochemistry 60:923–8.
   Web of Science ®Google Scholar
• Capasso M, Ayala F, Russo R, Avvisati RA, Asci R, Iolascon A. (2009). A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population. J Cancer Res Clin Oncol 135:1799–807.
   PubMed Web of Science ®Google Scholar
• Conne B, Stutz A, Vassalli JD. (2000). The 3′ untranslated region of messenger RNA: a molecular ‘hotspot’ for pathology? Nat Med 6:637–41.
   PubMed Web of Science ®Google Scholar
• Fukuen S, Fukuda T, Matsuda H, Sumida A, Yamamoto I, Inaba T, Azuma J. (2002). Identification of the novel splicing variants for the hPXR in human livers. Biochem Biophys Res Commun 298:433–8.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, He P, von Moltke LL, Court MH. (2008). The CYP3 Family. In: Ioannides C, editor. Cytochrome P450: Role in the metabolism and toxicology of drugs and other xenobiotics. London: Royal Society of Chemistry. p. 354–83.
   Google Scholar
• Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17.
   PubMed Web of Science ®Google Scholar
• He P, Court MH, Greenblatt DJ, von Moltke LL. (2005). Genotype–phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373–87.
   PubMed Web of Science ®Google Scholar
• He P, Court M, Greenblatt D, von Moltke L. (2006a). Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol 46:1356–69.
   PubMed Web of Science ®Google Scholar
• He P, Court MH, Greenblatt DJ, von Moltke LL. (2006b). Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 34:1198–207.
   PubMed Web of Science ®Google Scholar
• Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225–38.
   PubMedGoogle Scholar
• Hill WG. (1974). Estimation of linkage disequilibrium in randomly mating populations. Heredity 33:229–39.
   PubMed Web of Science ®Google Scholar
• Hughes TA. (2006). Regulation of gene expression by alternative untranslated regions. Trends Genet 22:119–22.
   PubMed Web of Science ®Google Scholar
• Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, Burk O. (2001). Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454–9.
   PubMed Web of Science ®Google Scholar
• King CR, Xiao M, Yu J, Minton MR, Addleman NJ, Van Booven DJ, Kwok PY, McLeod HL, Marsh S. (2007). Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol 63:547–54.
   PubMed Web of Science ®Google Scholar
• Koyano S, Kurose K, Ozawa S, Saeki M, Nakajima Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Nakajima T, Saito H, Kimura H, Goto Y, Saitoh O, Katoh M, Ohnuma T, Kawai M, Sugai K, Ohtsuki T, Suzuki C, Minami N, Saito Y, Sawada J (2002). Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations. Drug Metab Pharmacokinet 17:561–5.
   PubMedGoogle Scholar
• Koyano S, Kurose K, Saito Y, Ozawa S, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Nakajima T, Matsumoto K, Akasawa A, Saito H, Sawada J (2004). Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 32:149–54.
   PubMed Web of Science ®Google Scholar
• Lamba J, Lamba V, Schuetz E. (2005). Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6:369–83.
   PubMed Web of Science ®Google Scholar
• Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S, Schuetz EG. (2004). PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199:251–65.
   PubMed Web of Science ®Google Scholar
• Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–23.
   PubMed Web of Science ®Google Scholar
• Meijerman I, Beijnen JH, Schellens JH. (2006). Herb–drug interactions in oncology: focus on mechanisms of induction. Oncologist 11:742–52.
   PubMed Web of Science ®Google Scholar
• Olsen PH, Ambros V. (1999). The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 216:671–80.
   PubMed Web of Science ®Google Scholar
• Özdemir V, Kalowa WA, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. (2000). Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373–88.
   PubMedGoogle Scholar
• Spencer CC, Deloukas P, Hunt S, Mullikin J, Myers S, Silverman B, Donnelly P, Bentley D, McVean G. (2006). The influence of recombination on human genetic diversity. PLoS Genet 2:e148.
   Google Scholar
• Stephens M, Smith NJ, Donnelly P. (2001). A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–89.
   PubMed Web of Science ®Google Scholar
• Takagi S, Nakajima, M, Mohri, T, Yokoi, T. (2008). Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674–80.
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389–430.
   PubMed Web of Science ®Google Scholar
• Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. (2005). Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693–704.
   PubMed Web of Science ®Google Scholar
• Wang D, Sadee W. (2006). Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J 8:E515–20.
   PubMed Web of Science ®Google Scholar
• Westlind A, Löfberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. (1999). Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201–5.
   PubMed Web of Science ®Google Scholar
• Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. (2003). Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755–61.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. (1996). Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475–90.
   PubMedGoogle Scholar
• Wrighton SA, VandenBranden M, Ring BJ. (1996). The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 24:461–73.
   PubMedGoogle Scholar
• Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR Jr, Schuetz EG, Boguski MS (2001). The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555–72.
   PubMedGoogle Scholar